dengue tetravalent vaccine, live (Sanofi)

Dengvaxia (CYD-TDV) is a live attenuated tetravalent dengue vaccine developed by Sanofi Pasteur. It is a chimeric vaccine constructed using recombinant DNA technology, where the structural genes encoding the pre-membrane (prM) and envelope (E) proteins of the four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) are inserted into the genetic backbone of the attenuated yellow fever 17D vaccine virus. This design utilizes the yellow fever 17D strain's non-structural and capsid proteins to facilitate replication while inducing protective immune responses against all four dengue serotypes. It was the first dengue vaccine to be licensed, specifically indicated for individuals aged 9 to 45 (or 9 to 16 in the United States) who have laboratory-confirmed evidence of a previous dengue infection and live in endemic areas. Due to safety concerns regarding increased risk of severe dengue in seronegative individuals and low global market demand, Sanofi Pasteur announced the discontinuation of Dengvaxia production in 2025.

Other names

recombinant tetravalent dengue vaccinechimeric yellow fever-dengue virus tetravalent dengue vaccineCYD-1CYD1CYD 1CYD-2CYD2CYD 2CYD-3CYD3CYD 3CYD-4CYD4CYD 4